[Oireachtas] Dail Eireann debate. Written answer 761 - medicinal products availability. [30578/15] [Buprenorphine]. (22 Sep 2015)
Preview | Title | Contact |
---|---|---|
|
PDF (PQ response from HSE)
- Published Version
162kB |
External website: http://oireachtasdebates.oireachtas.ie/Debates%20A...
761. Deputy Caoimhghín Ó Caoláin asked the Minister for Health the number currently availing of a pilot scheme in which participants receive buprenorphine as opposed to methadone; the comparative cost of bought treatments; the comparative risk profile of both medications; and if he will make a statement on the matter. [30578/15]
Minister of State at the Department of Health (Deputy Aodhán Ó Ríordáin): I am advised by the Health Service Executive that at the end of July 2015 there were 77 people in receipt of buprenorphine/naloxone (Suboxone) for opioid dependence. Suboxone is being provided to this cohort under an initial feasibility study to evaluate the use of Suboxone in Ireland. I have asked the HSE to reply to the Deputy directly in relation to the comparative costs and risk profiles of both methadone and Suboxone.
If the Deputy has not received a reply from the HSE within 15 working days he should contact my Private Office and they will follow up the matter with them.
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution)
MP-MR Policy, planning, economics, work and social services > Economic aspects of substance use (cost / pricing)
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page